Followers | 59 |
Posts | 2166 |
Boards Moderated | 1 |
Alias Born | 02/18/2014 |
Sunday, October 22, 2017 9:59:52 PM
Posted by Stefani Robinson on Oct 22nd, 2017
Genocea Biosciences logoShares of Genocea Biosciences, Inc. (NASDAQ:GNCA) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.47.
A number of equities research analysts recently commented on GNCA shares. Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday, July 24th. Zacks Investment Research downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company restated an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, July 25th. ValuEngine downgraded shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 price target (up from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th.
In other news, CFO Jonathan Poole sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at approximately $505,482. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of GNCA. GSA Capital Partners LLP purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $100,000. Ameriprise Financial Inc. increased its stake in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 2,300 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $125,000. Rhumbline Advisers purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $157,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $159,000. 59.25% of the stock is owned by institutional investors and hedge funds.
Shares of Genocea Biosciences (GNCA) traded up 4.29% during trading on Thursday, hitting $1.46. The company had a trading volume of 763,900 shares. The firm’s market capitalization is $41.79 million. Genocea Biosciences has a 52-week low of $1.13 and a 52-week high of $7.29. The stock’s 50-day moving average is $3.24 and its 200 day moving average is $4.97.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Equities research analysts predict that Genocea Biosciences will post ($1.92) earnings per share for the current fiscal year.
https://www.truebluetribune.com/2017/10/22/analysts-set-genocea-biosciences-inc-gnca-price-target-at-7-47.html
All Posts About Stock Performance Are Of My Own Opinion!
Click Here For Bounce Plays!!!
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM